Trilogy International Partners Inc T.TRL.WT.A

BNN: Expect Licensing Deal

[LTOWNER]

"If it does work out it could be a huge win".  This afternoon Peter Imhof, Investment Strategist at Sprott Asset Management for Canadian Small Caps, called Trimel "an interesting story".  He said it has gotten a lot of attention because it is working on a female Viagra, and its main drug is for male testosterone - needed because bones get brittle with age - is in trials

 

It did not sound like he was up on the preliminary results out yesterday but he did say we "should expect a licensing deal with one of the bigger pharma companies" in the next few months and "that will be the catalyst."

 

Said Trimel is still a concept stock; it has done fairly well but there will be a downside if trials don't go well.